Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
10 Noviembre 2009 - 3:05PM
PR Newswire (US)
RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transcept
Pharmaceuticals, Inc. (NASDAQ:TSPT) today announced that it will
present at the Lazard Capital Markets 6th Annual Healthcare
Conference on Tuesday, November 17, at 2:10 p.m. Eastern Standard
Time. A live audio webcast and replay of the presentation will be
available on the Transcept investor webpage at
http://www.transcept.com/. About Transcept Transcept
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of proprietary products
that address important therapeutic needs in neuroscience. The most
advanced Transcept product candidate is Intermezzo® (zolpidem
tartrate sublingual tablet), for which a New Drug Application (NDA)
was submitted to the U.S. Food and Drug Administration (FDA) in
September 2008 seeking approval as a prescription sleep aid for use
in the middle of the night at the time a patient awakens and has
difficulty returning to sleep. In October 2009, Transcept received
a Complete Response Letter from the FDA on the Intermezzo® NDA and
is working to respond to issues raised in the letter. Transcept and
Purdue Pharmaceutical Products, L.P. have entered into a
collaboration agreement for the development and commercialization
of Intermezzo® in the United States. For further information,
please visit the company's website at: http://www.transcept.com/.
Contact: Transcept Pharmaceuticals, Inc. Greg Mann Director,
Corporate Communications (510) 215-3567 DATASOURCE: Transcept
Pharmaceuticals, Inc. CONTACT: Greg Mann, Director, Corporate
Communications of Transcept Pharmaceuticals, Inc., +1-510-215-3567,
Web Site: http://www.transcept.com/
Copyright